+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of L-Carnitine Supplementation in Hemodialysis Patients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background/Aim: L-Carnitine is important in β-oxidation of fatty acids. A lack of carnitine in hemodialysis patients is caused by insufficient carnitine synthesis and especially by its loss during dialysis. The aim of our study was to test the influence of carnitine supplementation on plasma lipids, red blood cell count, and metabolism of free radicals. Methods: Twelve regularly dialyzed patients (average age 55.5 years, average dialysis treatment period 22.5 months) were given 15 mg/kg L-carnitine intravenously three times weekly (after each hemodialysis session) for 6 months. Laboratory markers of oxidative stress, lipid metabolism, and red blood cell count were measured before the supplementation and then controlled during two 3-month intervals. Nine patients were retested 3 months after the supplementation had ended. Results: All supplemented patients showed increased plasma free carnitine in comparison with the pretreatment values (113.3 ± 11.2 vs. 62.3 ± 16.7 µmol/l, p < 0.001). The proportion of decreased L-carnitine values after hemodialysis was reduced from 79 to 22%. Plasma total cholesterol (4.66 ± 0.30 mmol/l after treatment vs. 5.65 ± 1.53 mmol/l before treatment, p < 0.05) and LDL cholesterol (1.74 ± 0.86 vs. 2.81 ± 1.43 mmol/l, p < 0.05) decreased. The albumin concentration significantly increased from 34.8 ± 7.3 to 46.0 ±5.4 g/l (p < 0.05). Intraerythrocyte reduced glutathione increased from 1.65 ± 0.25 to 2.23 ± 0.16 mmol/l (p < 0.001), and the plasma antioxidant capacity increased from 1.65 ± 0.09 to 2.06 ± 0.17 mmol/l (p < 0.001). At the same time, plasma malondialdehyde decreased from 4.18 ± 0.72 to 3.07 ± 0.35 µmol/l (p < 0.001). The erythropoietin dose could be reduced from an average value of 5,500 to 3,500 U/week. No significant changes in the above-mentioned parameters were observed in a control group of dialyzed patients without L-carnitine supplementation. Conclusion: Regular carnitine supplementation of hemodialysis patients can improve their lipid metabolism, protein nutrition, red blood cell count, and antioxidant status.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: not found
          • Article: not found

          Effect of L-carnitine and acetyl-L-carnitibe on the human erythrocyte membrane stability and deformability


            Author and article information

            S. Karger AG
            22 June 2001
            : 88
            : 3
            : 218-223
            aHemodialysis Center EuroCare, Pilsen, bInstitute of Clinical Biochemistry and Laboratory Diagnostics, Charles University Hospital, Pilsen, and cDepartment of Internal Medicine, Military Hospital, Pilsen, Czech Republic
            45993 Nephron 2001;88:218–223
            © 2001 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Figures: 2, Tables: 3, References: 21, Pages: 6
            Self URI (application/pdf): https://www.karger.com/Article/Pdf/45993
            Original Paper


            Comment on this article